

# PRODUCT INFORMATION




## Iodixanol

Item No. 35020

**CAS Registry No.:** 92339-11-2  
**Formal Name:** 5,5'-[(2-hydroxy-1,3-propanediyl)bis(acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide]

**MF:** C<sub>35</sub>H<sub>44</sub>I<sub>6</sub>N<sub>6</sub>O<sub>15</sub>  
**FW:** 1,550.2  
**Purity:** ≥95% (mixture of isomers)  
**UV/Vis.:** λ<sub>max</sub>: 246 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Iodixanol is supplied as a solid. A stock solution may be made by dissolving the iodixanol in the solvent of choice, which should be purged with an inert gas. Iodixanol is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of iodixanol in these solvents is approximately 15 and 30 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of iodixanol can be prepared by directly dissolving the solid in aqueous buffers. The solubility of iodixanol in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Iodixanol is a nonionic, water-soluble contrast reagent.<sup>1</sup> It induces apoptosis and mitophagy in renal epithelial cells in a rat model of contrast-induced acute kidney injury.<sup>2</sup> Iodixanol has also been used as a density gradient medium in the fractionation of plasma lipoproteins.<sup>3</sup> Formulations containing iodixanol have been used for the visualization of arteries, veins, the urinary tract, head, and body using X-ray and computed tomography (CT) scan imaging techniques.

### References

1. Almén, T. Visipaque - a step forward: A historical review. *Acta Radiol.* **57(5)**, e47-e63 (1995).
2. Cheng, W., Zhao, F., Tang, C.-Y., *et al.* Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model. *Arch. Toxicol.* **92(7)**, 2245-2257 (2018).
3. Graham, J.M., Higgins, J.A., Gillott, T., *et al.* A novel method for the rapid separation of plasma lipoproteins using self-generating gradients of iodixanol. *Atherosclerosis* **124(1)**, 125-135 (1996).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/28/2021

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM